U Pittsburgh team develops online tool for ovarian cancer symptom management

Elahere demonstrates OS, PFS benefit regardless of prior PARPi exposure or prior lines of therapy in ovarian cancer

Findings from two subset analyses of the phase III MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer demonstrate an overall survival and progression-free survival benefit.

September 29, 2023

Vol.49 No.36

Clinical Roundup

City of Hope researchers develop a CAR T-cell therapy for advanced ovarian cancer, now in phase I

City of Hope researchers published preclinical research in Nature Communications demonstrating that a CAR-engineered T-cell therapy worked against ovarian cancer in the laboratory and in preclinical models.

August 11, 2023

Vol.49 No.32

Clinical Roundup

Researchers identify biological signature that may identify refractory ovarian cancer patients

Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Center, and University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.

August 11, 2023

Vol.49 No.32

In Brief

Sudhir Srivastava receives Ruth C. Brufsky Award for Excellence in Clinical Research in Pancreatic Cancer

Sudhir Srivastava will receive the Ruth C. Brufsky Award for Excellence in Clinical Research in Pancreatic Cancer at the PancreasFest 2023, held July 26-28 at The University of Pittsburgh.

June 02, 2023

Vol.49 No.22

Clinical Roundup

Hysterectomy doesn’t mitigate ovarian cancer risk in Black women with endometriosis, Fred Hutch study shows

A Fred Hutchinson Cancer Center study, published in Obstetrics & Gynecology,investigated how endometriosis, uterine leiomyomas (also known as fibroids), and a common intervention for these conditions—hysterectomy—changed ovarian cancer risk in Black and white women.

May 12, 2023

Vol.49 No.19

Regulatory News

ODAC says prostate cancer patients who lack proven BRCA mutation shouldn’t get PARP inhibitor

The FDA Oncologic Drugs Advisory Committee agreed with the agency’s forcefully stated view that Lynparza (olaparib), a PARP inhibitor, should be given only to metastatic castration-resistant prostate cancer patients whose tumors have a BRCA mutation.

May 05, 2023

Vol.49 No.18

By Paul Goldberg

U Pittsburgh team develops online tool for ovarian cancer symptom management

YOU MAY BE INTERESTED IN

Elahere demonstrates OS, PFS benefit regardless of prior PARPi exposure or prior lines of therapy in ovarian cancer

City of Hope researchers develop a CAR T-cell therapy for advanced ovarian cancer, now in phase I

Researchers identify biological signature that may identify refractory ovarian cancer patients

Sudhir Srivastava receives Ruth C. Brufsky Award for Excellence in Clinical Research in Pancreatic Cancer

Hysterectomy doesn’t mitigate ovarian cancer risk in Black women with endometriosis, Fred Hutch study shows

ODAC says prostate cancer patients who lack proven BRCA mutation shouldn’t get PARP inhibitor

Renew today!

Subscriber content

Login